ijms-logo

Journal Browser

Journal Browser

Tissue Engineering in Brain Injury Applications: From Molecular Mechanisms to Therapeutics Opportunities

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (30 November 2020) | Viewed by 7013

Special Issue Editor


E-Mail Website
Guest Editor
Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117594, Singapore
Interests: brain injury; tissue infections; inflammation; diabetes; microbiome; diagnostics; engineering; nanoparticles; drug development; drug delivery

Special Issue Information

Brain injury is one of the most pressing global health issues and prevalent causes of cerebrovascular and neurological disorders all over the world. In addition to the brain injury, patients become vulnerable to infections, develop poor neurological outcomes, and exhibit a higher rate of mortality and morbidity. It is well established that brain injury leads to impairments of the blood–brain barrier (BBB) integrity and function, contributing to the loss of neural tissue and affecting the response to neuroprotective drugs. Thus, stabilization/protection of the BBB after brain injury is a promising strategy to limit neuronal inflammation, secondary brain damage, and acute neurodegeneration.

This Special Issue will be an open-access forum to address these issues, in the form of original research articles and reviews about “Tissue Engineering in Brain Injury Applications: From Molecular Mechanisms to Therapeutics Opportunities”. The Special Issue is aimed at researchers using a wide range of tissue infection models, which may include animal models, ex vivo tissues, and reconstructed or engineered tissues, using physical, biochemical, and immunological techniques to study host–pathogen interactions, the microbiome, the role of predisposing factors (e.g., diabetes), inflammation, new drugs, and infection management techniques and diagnostics. We hope to stimulate new collaborations, therapeutic avenues, and technologies to advance our field and to expand the range of treatments available to clinicians

Prof. Dr. Dinesh Kumar Srinivasan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Brain injury
  • Tissue infections
  • Inflammation
  • Diabetes
  • Microbiome
  • Diagnostics
  • Engineering
  • Nanoparticles
  • Drug development
  • Drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

32 pages, 4946 KiB  
Review
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders
by Tao Ming Sim, Dinesh Tarini, S. Thameem Dheen, Boon Huat Bay and Dinesh Kumar Srinivasan
Int. J. Mol. Sci. 2020, 21(17), 6070; https://doi.org/10.3390/ijms21176070 - 23 Aug 2020
Cited by 37 | Viewed by 6503
Abstract
Neurological disorders are the most devastating and challenging diseases associated with the central nervous system (CNS). The blood-brain barrier (BBB) maintains homeostasis of the brain and contributes towards the maintenance of a very delicate microenvironment, impairing the transport of many therapeutics into the [...] Read more.
Neurological disorders are the most devastating and challenging diseases associated with the central nervous system (CNS). The blood-brain barrier (BBB) maintains homeostasis of the brain and contributes towards the maintenance of a very delicate microenvironment, impairing the transport of many therapeutics into the CNS and making the management of common neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), cerebrovascular diseases (CVDs) and traumatic brain injury (TBI), exceptionally complicated. Nanoparticle (NP) technology offers a platform for the design of tissue-specific drug carrying systems owing to its versatile and modifiable nature. The prospect of being able to design NPs capable of successfully crossing the BBB, and maintaining a high drug bioavailability in neural parenchyma, has spurred much interest in the field of nanomedicine. NPs, which also come in an array of forms including polymeric NPs, solid lipid nanoparticles (SLNs), quantum dots and liposomes, have the flexibility of being conjugated with various macromolecules, such as surfactants to confer the physical or chemical property desired. These nanodelivery strategies represent potential novel and minimally invasive approaches to the treatment and diagnosis of these neurological disorders. Most of the strategies revolve around the ability of the NPs to cross the BBB via various influx mechanisms, such as adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT), targeting specific biomarkers or lesions unique to that pathological condition, thereby ensuring high tissue-specific targeting and minimizing off-target side effects. In this article, insights into common neurological disorders and challenges of delivering CNS drugs due to the presence of BBB is provided, before an in-depth review of nanoparticle-based theranostic strategies. Full article
Show Figures

Figure 1

Back to TopTop